{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:40:02Z","timestamp":1747125602667,"version":"3.40.5"},"reference-count":98,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2843","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T07:40:25Z","timestamp":1743493225000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Inextricable association of connective tissue disease with B\u2011cell lymphoma (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Jing-Shu","family":"Ruan","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ning","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"key20250513105836_b1-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/aje\/kwu290","article-title":"Associations of non-Hodgkin lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci","volume":"181","author":"Wang","year":"2015","journal-title":"Am J Epidemiol"},{"key":"key20250513105836_b2-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1067\/j.cpradiol.2021.07.007","article-title":"Chest high-resolution computed tomography in patients with connective tissue disease: Pulmonary conditions beyond \u2018the usual suspects\u2019","volume":"51","author":"Cereser","year":"2022","journal-title":"Curr Probl Diagn Radiol"},{"issue":"102945","key":"key20250513105836_b3-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102945","article-title":"Lymphoma in the setting of autoimmune diseases: A review of association and mechanisms","volume":"150","author":"Khanmohammadi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20250513105836_b4-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2007.02.002","article-title":"Autoimmunity and malignancy in hematology-more than an association","volume":"63","author":"Stern","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20250513105836_b5-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1006\/bcmd.2001.0442","article-title":"The dual association between lymphoma and autoimmunity","volume":"27","author":"Ehrenfeld","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"key20250513105836_b6-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","article-title":"Malignant lymphoma-associated autoimmune diseases-a descriptive epidemiological study","volume":"22","author":"V\u00e1r\u00f3czy","year":"2002","journal-title":"Rheumatol Int"},{"key":"key20250513105836_b7-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"key20250513105836_b8-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/10428199909093729","article-title":"Lymphomas in patients with Sj\u00f6gren's syndrome: Review of the literature and physiopathologic hypothesis","volume":"33","author":"Mariette","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"key20250513105836_b9-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(00)02481-8","article-title":"Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French coeliac disease study group","volume":"356","author":"Cellier","year":"2000","journal-title":"Lancet"},{"issue":"16039","key":"key20250513105836_b10-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key20250513105836_b11-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1136\/ard.2004.034504","article-title":"Non-Hodgkin's lymphoma in systemic lupus erythematosus","volume":"64","author":"Bernatsky","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b12-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12026-016-8885-8","article-title":"Correlation between systemic lupus erythematosus and malignancies: A cross-sectional population-based study","volume":"65","author":"Azrielant","year":"2017","journal-title":"Immunol Res"},{"key":"key20250513105836_b13-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/ard.51.4.437","article-title":"Increased risk of cancer in patients with systemic lupus erythematosus","volume":"51","author":"Pettersson","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b14-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1191\/096120301678646128","article-title":"Systemic lupus erythematosus and the risk of malignancy","volume":"10","author":"Cibere","year":"2001","journal-title":"Lupus"},{"key":"key20250513105836_b15-MCO-22-6-02843","first-page":"1478","article-title":"Risk of malignancy in women with systemic lupus erythematosus","volume":"22","author":"Sweeney","year":"1995","journal-title":"J Rheumatol"},{"key":"key20250513105836_b16-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/art.1780390625","article-title":"Malignancy in systemic lupus erythematosus","volume":"39","author":"Abu-Shakra","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b17-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.1780400424","article-title":"Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus","volume":"40","author":"Mellemkler","year":"1997","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b18-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10067-006-0532-7","article-title":"Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL)","volume":"26","author":"King","year":"2007","journal-title":"Clin Rheumato"},{"key":"key20250513105836_b19-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","article-title":"Rheumatoid arthritis: Early diagnosis and treatment","volume":"105","author":"Cush","year":"2021","journal-title":"Med Clin North Am"},{"key":"key20250513105836_b20-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"key20250513105836_b21-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isom\u00e4ki","year":"1978","journal-title":"J Chron Dis"},{"key":"key20250513105836_b22-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"key20250513105836_b23-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/a:1018472213872","article-title":"Elevated incidence of hematologic malignancies in patients with Sj\u00f6gren's syndrome compared with patients with rheumatoid arthritis (Finland)","volume":"8","author":"Kauppi","year":"1997","journal-title":"Cancer Causes Control"},{"key":"key20250513105836_b24-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0002-9343(85)90240-2","article-title":"Cancer and rheumatoid arthritis: epidemiologic considerations","volume":"78","author":"Prior","year":"1985","journal-title":"Am J Med"},{"key":"key20250513105836_b25-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9343(85)90242-6","article-title":"Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland","volume":"78","author":"Hakulinen","year":"1985","journal-title":"Am J Med"},{"key":"key20250513105836_b26-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study","volume":"47","author":"Silman","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b27-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.v99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"key20250513105836_b28-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0002-9343(85)90245-1","article-title":"Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment","volume":"78","author":"Kinlen","year":"1985","journal-title":"Am J Med"},{"key":"key20250513105836_b29-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"438","DOI":"10.12968\/hmed.2017.78.8.438","article-title":"Sj\u00f6gren's syndrome","volume":"78","author":"Thorne","year":"2017","journal-title":"Br J Hosp Med (Lond)"},{"key":"key20250513105836_b30-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American college of rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key20250513105836_b31-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5114\/reum.2019.89520","article-title":"Classification criteria for secondary Sj\u00f6gren's syndrome. Current state of knowledge","volume":"57","author":"Sebastian","year":"2019","journal-title":"Reumatologia"},{"key":"key20250513105836_b32-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann Intern Med"},{"key":"key20250513105836_b33-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10067-011-1807-1","article-title":"Malignant lymphomas and autoimmunity-a single center experience from Hungary","volume":"31","author":"V\u00e1r\u00f3czy","year":"2012","journal-title":"Clin Rheumatol"},{"key":"key20250513105836_b34-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: A meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"key20250513105836_b35-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/ard.60.5.467","article-title":"A longitudinal cohort study of Finnish patients with primary Sj\u00f6gren's syndrome: Clinical, immunological, and epidemiological aspects","volume":"60","author":"Pertovaara","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b36-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/01.bor.0000209423.39033.94","article-title":"Malignancy and autoimmunity","volume":"18","author":"Bernatsky","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"key20250513105836_b37-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nri953","article-title":"Lymphoid malignancies: The dark side of B-cell differentiation","volume":"2","author":"Shaffer","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"key20250513105836_b38-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstr\u00f6m","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b39-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1055-9965.EPI-06-1070","article-title":"Altered immunity as a risk factor for non-Hodgkin lymphoma","volume":"16","author":"Grulich","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20250513105836_b40-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1177\/09612033221114578","article-title":"Exploration of the molecular mechanisms, shared gene signatures, and MicroRNAs between systemic lupus erythematosus and diffuse large B cell lymphoma by bioinformatics analysis","volume":"31","author":"Peng","year":"2022","journal-title":"Lupus"},{"issue":"1036239","key":"key20250513105836_b41-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1036239","article-title":"Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"key20250513105836_b42-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ni0901-793","article-title":"Autoimmunity and lymphoma: Tribulations of B cells","volume":"2","author":"Mackay","year":"2001","journal-title":"Nature Immunol"},{"key":"key20250513105836_b43-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-f","article-title":"Regression of primary lowgrade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori","volume":"324","author":"Wotherspoon","year":"1993","journal-title":"Lancet"},{"key":"key20250513105836_b44-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/ard.60.11.1007","article-title":"Lymphomas complicating Sj\u00f6gren's syndrome and hepatitis C virus infection may share a common pathogenesis: Chronic stimulation of rheumatoid factor B cells","volume":"60","author":"Mariette","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b45-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20250513105836_b46-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"key20250513105836_b47-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11926-002-0045-6","article-title":"Malignancy and systemic lupuserythematosus","volume":"4","author":"Bernatsky","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"key20250513105836_b48-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s1568-9972(02)00121-0","article-title":"Pathogenesis of Sjogren's syndrome","volume":"2","author":"Yamamoto","year":"2003","journal-title":"Autoimmun Rev"},{"key":"key20250513105836_b49-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","article-title":"Rheumatoid arthritis and malignant lymphomas","volume":"16","author":"Baecklund","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"key20250513105836_b50-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"key":"key20250513105836_b51-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"15701","key":"key20250513105836_b52-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.1038\/srep15701","article-title":"IL-6 inhibits starvation-induced autophagy via the STAT3\/Bcl-2 signaling pathway","volume":"5","author":"Qin","year":"2015","journal-title":"Sci Rep"},{"key":"key20250513105836_b53-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1182\/blood-2005-10-4160","article-title":"Cytokine polymorphisms in the Th1\/Th2 pathway and susceptibility to non-Hodgkin lymphoma","volume":"107","author":"Lan","year":"2006","journal-title":"Blood"},{"key":"key20250513105836_b54-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/10428199709051774","article-title":"Interleukin-10 in non-Hodgkin's lymphoma","volume":"26","author":"Cortes","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"key20250513105836_b55-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s002620050483","article-title":"A review of the association between interleukin-10 and human B-cell malignancies","volume":"46","author":"Khatri","year":"1998","journal-title":"Cancer Immunol Immunother"},{"key":"key20250513105836_b56-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1006\/meth.1996.0397","article-title":"Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity","volume":"11","author":"Emilie","year":"1997","journal-title":"Methods"},{"key":"key20250513105836_b57-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","article-title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph consortium","volume":"7","author":"Rothman","year":"2006","journal-title":"Lancet Oncol"},{"key":"key20250513105836_b58-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","article-title":"The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sj\u00f6gren's syndrome","volume":"62","author":"Szodoray","year":"2005","journal-title":"Scand J Immunol"},{"key":"key20250513105836_b59-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","article-title":"Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome","volume":"104","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"key20250513105836_b60-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b61-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/art.1780390223","article-title":"Methotrexate-associated lymphoma in patients with rheumatoid arthritis: Report of two cases","volume":"39","author":"Bachman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b62-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/ard.42.4.368","article-title":"The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up","volume":"42","author":"Baltus","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b63-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/ard.43.2.132","article-title":"Lymphoproliferative malignancy in rheumatoid arthritis: A study of 20 cases","volume":"43","author":"Symmons","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b64-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"key":"key20250513105836_b65-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/annrheumdis-2012-202099","article-title":"Lymphoma risk in systemic lupus: Effects of disease activity versus treatment","volume":"73","author":"Bernatsky","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b66-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b67-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b68-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20250513105836_b69-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20250513105836_b70-MCO-22-6-02843","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"key20250513105836_b71-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1200\/JCO.2006.07.5671","article-title":"Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis","volume":"24","author":"Ghesqui\u00e8res","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20250513105836_b72-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"key20250513105836_b73-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update","volume":"264","author":"Smedby","year":"2008","journal-title":"J Intern Med"},{"key":"key20250513105836_b74-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2008-07-168773","article-title":"A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo","volume":"113","author":"Cerchietti","year":"2009","journal-title":"Blood"},{"key":"key20250513105836_b75-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"key20250513105836_b76-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","article-title":"Pathogenesis of non-Hodgkin's lymphoma","volume":"29","author":"Nogai","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20250513105836_b77-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/0959-8049(95)00367-3","article-title":"Non-Hodgkin's lymphomas-current status of therapy and future perspectives","volume":"31A","author":"Hiddemann","year":"1995","journal-title":"Eur J Cancer"},{"key":"key20250513105836_b78-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large B-cell lymphoma: Does subtype make a difference in therapy selection?","volume":"35","author":"Nowakowski","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20250513105836_b79-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20250513105836_b80-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low-grade lymphoma study group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"key20250513105836_b81-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"key20250513105836_b82-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"686","key":"key20250513105836_b83-MCO-22-6-02843","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study","volume":"120","author":"Wilson","year":"2012","journal-title":"Blood"},{"key":"key20250513105836_b84-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"key20250513105836_b85-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"key20250513105836_b86-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40266-017-0468-4","article-title":"Current status of Bruton's tyrosine kinase inhibitor development and use in B-cell malignancies","volume":"34","author":"Aw","year":"2017","journal-title":"Drugs Aging"},{"key":"key20250513105836_b87-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20250513105836_b88-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20250513105836_b89-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1080\/14656566.2020.1791083","article-title":"Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies","volume":"21","author":"Smolewski","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"key20250513105836_b90-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20250513105836_b91-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"key20250513105836_b92-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","article-title":"ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia","volume":"121","author":"Vandenberg","year":"2013","journal-title":"Blood"},{"issue":"3353","key":"key20250513105836_b93-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113353","article-title":"BH3 mimetics for the treatment of B-cell malignancies-insights and lessons from the clinic","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20250513105836_b94-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"938","key":"key20250513105836_b95-MCO-22-6-02843","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20250513105836_b96-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1586\/ehm.09.24","article-title":"Transplantation for non-Hodgkin lymphoma","volume":"2","author":"Nademanee","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"key20250513105836_b97-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.hoc.2014.08.015","article-title":"Hematopoietic stem cell transplantation for non-Hodgkin lymphoma","volume":"28","author":"Bhatt","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20250513105836_b98-MCO-22-6-02843","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1080\/10428194.2020.1762879","article-title":"Autograft cellular composition and outcome in NHL patients: Results of the prospective multicenter GOA study","volume":"61","author":"Turunen","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:58:43Z","timestamp":1747123123000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":98,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2843","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"type":"print","value":"2049-9450"},{"type":"electronic","value":"2049-9469"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}